Bortezomib 2mg Injection is a medication used in the treatment of multiple myeloma and certain types of lymphoma. It is administered by injection into a vein (intravenously) under the supervision of a healthcare professional. By blocking proteasome activity, bortezomib disrupts the normal functioning of cancer cells and induces cell death. This works by inhibiting the activity of proteasomes, which are protein complexes that play a critical role in the regulation of cell growth and survival. Bortezomib 2mg Injection is effective in the treatment of multiple myeloma and mantle cell lymphoma, both as a first-line treatment and in patients who have relapsed or are refractory to other therapies.
Specification
Manufactured By |
Natco Pharma Ltd |
Brand |
Natco |
Dose/Strength |
2 mg |
Packaging Type |
Vial |
Shelf life |
24 month |
Usage/Application |
Clinical |